185750 — Chong Kun Dang Pharmaceutical Share News
0.000.00%
Last trade - 00:00- KR₩829bn
- KR₩940bn
- KR₩2tn
Brief: Chong Kun Dang Pharmaceutical Corp To Invest 392.5 Billion Won In Research Centre And Other Facility
Brief: Chong Kun Dang Pharmaceutical Q1 Operating Profit 17.6 Billion Won, Up 37% From Year Earlier
Brief: Chong Kun Dang Pharmaceutical Q3 Operating Profit 20.5 Billion Won, Down 19% From Year Earlier
Brief: Chong Kun Dang Pharmaceutical To Divest 61 Billion Won Worth Of Own Shares
Brief: Chong Kun Dang Pharmaceutical Q1 Operating Profit 12.8 Billion Won, Down 52% From Year Earlier
Brief: Chong Kun Dang Pharmaceutical Q2 Operating Profit 28.4 Billion Won, Down 34.6% From Year Earlier
Brief: Chong Kun Dang Pharmaceutical Q1 Operating Profit 27 Billion Won, Down 11% From Year Earlier
Brief: Chong Kun Dang Pharmaceutical Signed $1.3 Billion Technology Transfer Deal With Novartis
Brief: Chong Kun Dang Pharmaceutical Q3 Operating Profit 53 Billion Won, Up 34% From Year Earlier
Brief: Chong Kun Dang Pharmaceutical Q2 Operating Profit 43.4 Billion Won, Up 54.4% From Year Earlier
Brief: Chong Kun Dang Pharmaceutical Q1 Operating Profit 30 Billion Won, Up 24% From Year Earlier
Brief: Chong Kun Dang Pharmaceutical Q1 Operating Profit Falls 13 Percent Y/Y
Brief: Can-Fite Expands Its Namodenoson Distribution Deal With CKD In South Korea With Nash Indication
Brief: Chong Kun Dang Announces Bonus Issue Of 491,054 New Shares
Brief: Chong Kun Dang Pharmaceutical receives Europe patent
Brief: Chong Kun Dang Pharmaceutical receives U.S. patent
Brief: Chong Kun Dang Pharmaceutical to pay annual dividend as 900 won/share for FY 2016
Brief: Chong Kun Dang Pharmaceutical receives patent
Brief: Can-Fite signs distribution deal for liver cancer drug CF102 in South Korea